The widely used TCHP chemotherapy regimen is weakening under scrutiny. Multiple randomized trials now show that adding carboplatin (the 'C') provides no additional benefit in shrinking tumors but increases toxicity, directly challenging its standing as a recommended standard of care in guidelines.
As neoadjuvant therapies become more potent, they create complex post-treatment tissue changes. This makes it incredibly difficult for pathologists—the ultimate arbiters of treatment success—to assess residual disease and surgical margins, leading to significant interpretation variability that directly impacts subsequent patient care.
While powerful drugs effectively shrink tumors, the response pattern can be a "splatter" rather than a uniform deflation. This creates a significant surgical challenge, making it difficult to define clear margins for breast-conserving surgery and potentially necessitating a more extensive operation despite a good therapeutic response.
A speaker highlights that the Destiny-Breast05 trial (with a survival endpoint) was published in the prestigious New England Journal of Medicine, while the Destiny-Breast11 trial (with a tumor response endpoint) was rejected. This reveals an academic bias where top-tier journals prioritize hard outcomes like survival over surrogate endpoints.
The core conflict in choosing breast cancer therapy is whether to prioritize immediate tumor shrinkage (pathological complete response) or long-term cure (event-free survival). One trial (DB11) excels at shrinkage but isn't designed to prove survival, while another (DB05) proves survival, crystallizing a fundamental debate about clinical trial endpoints and treatment goals.
The risk of serious interstitial lung disease (ILD) with the drug TDXD is heavily dependent on the total duration of therapy. A short, 4-cycle neoadjuvant course has a low 4% ILD rate, whereas a longer 14-cycle adjuvant course sees this risk more than double to over 10%, making the shorter pre-surgical approach significantly safer.